NICE! Neurologists Find Replicable SARS-CoV-2 RNA In Cerebrospinal Fluid Of A Woman 114 Days After She Was Diagnosed With Asymptomatic COVID-19!
Source: SARS-CoV-2 Viral Persistence Oct 17, 2021 2 years, 6 months, 2 weeks, 5 days, 4 hours, 38 minutes ago
SARS-CoV-2 Viral Persistence: The COVID-19 pandemic is the best thing that has happened to mankind so far as it shows how incompetent most medical researchers and physicians are and worst, those ignorant bureaucratic developing medical and treatment guidelines from diagnostics, treatments, clinical practices etc. It also reflects on even how stupid majority of the masses are in accepting things and not even to question issues etc. It shows us how a small group of elites are controlling all narratives and it shows us the power of the big pharma conglomerates.
.jpg)
The diagnostic procedures for COVID-19 still remains one of the most stupid things I have ever came across and worse the protocols for terming an individual as having recovered from the SARS-CoV-2 infection ie using nasal swabs test! I have stressed this before and will continue doing so till the COVID-19 pandemic ends in about a decade or so.
In the last few months, we have been having physicians stating in many published clinical case reports about individuals being found in chronic conditions weeks after being deemed ‘recovered’ in which detailed biopsies or diagnostics and in some cases, autopsies after the individuals died, showing SARS-CoV-2 RNA in the blood, liver, lungs, kidneys, testes etc .
Now a team of neurologists and physicians from the Faculty Hospital Nové Zámky at Charles University-Hradec Králové, Czech Republic have published a clinical case report of a finding replicable SARS-CoV-2 RNA in cerebrospinal fluid of a woman 114 days after she was diagnosed with asymptomatic COVID-19!
The study highlights the often ignored issue of
SARS-CoV-2 Viral Persistence!
The study findings were published in the peer reviewed journal: Therapeutic Advances in Infectious Disease (SAGE Journals).
https://journals.sagepub.com/doi/full/10.1177/20499361211048572
The 42-year-old woman was initially tested positive for SARS-CoV-2 via nasal swab test and only had slight coughing and diarrhea. 10 days later, another nasal swab test showed negative results and she was asymptomatic and deemed as having recovered.
However, after about 4 to 5 weeks, she started having mild symptoms again and two weeks later started experiencing what many were considered as Long COVID conditions ie fatigue, anxiety etc.
The physicians reported that on 27 January 2021, she was hospitalized with a progressive headache, dizziness, anxiety, palpitations, diarrhea, and panic attacks. Neurological examination revealed hyperreflexia in the lower limbs and malaise. Routine blood tests, basic immunological and serological screening, and anti-neuronal antibodies were all negative. Brain magnetic resonance and electroencephalography showed no pathological changes. Detailed psychological and psychiatric assessment revealed increased tension and depression, which was not present before.
A 24-h electrocardiography (ECG) monitoring confirmed sinus tachycardia, and a transthoracic echocardiogram showed no abnormalities.
It was also noted that antigen and RT-PCR tests for SARS-CoV-2 from nasopharyngeal swabbing were negative at the time of ad
mission, but the study team confirmed detectable serum nucleocapsid immunoglobulin G (IgG) antibodies against SARS-CoV-2 (the patient had not been previously vaccinated against COVID-19 and anti-spike antibodies were not tested).
The patient’s cerebrospinal fluid (CSF) analysis showed mild elevation of protein (0.505 g/l) and lactate dehydrogenase (LDH) (0.57 μkat/l), although other parameters were in normal ranges (neutrophil count, 2 cells/μl; lymphocyte count, 0 cell/μl; erythrocyte count, 10 cells/μl; lactate, 1.55 mmol/l; glucose, 3.75 mmol/l; chloride, 128 mmol/l).
Further CSF studies for bacteria, mycobacteria, fungi, and common neurotropic viruses were negative, as was an evaluation of oligoclonal bands.
The study team next performed RT-PCR for the detection of SARS-CoV-2 RNA in the CSF was performed with Charité/Berlin primers and probes, targeting E gene for the coronavirus screening and RdRp gene as the confirmatory assay.
.jpg)
Briefly, viral RNA was stabilized in CSF with equal volume of DNA/RNA Shield solution (ZymoResearch, CA, USA) and aliquoted to prevent RNA degradation and contamination of the original sample. Viral RNA was extracted from the CSF using Quick-RNA Viral Kit (ZymoResearch, CA, USA), and RT-PCR assays were performed using Reliance One-Step Multiplex RT-PCR Supermix (Bio-Rad Laboratories, CA, USA) in CFX96 Touch Real-Time detection system (Bio-Rad). Thermal cycling ran at 55°C for 10 min for reverse transcription, followed by denaturation for 10 min at 95°C and then 45 amplification cycles: 10 s at 95°C and 30 s at 58°C.
The CSF was tested in three replicates for each gene and was considered clearly positive at cycle threshold (Ct) of 38.94, 37.22, and 38.17, respectively, for the RdRp gene. The time between the first positive nasopharyngeal SARS-CoV-2 RT-PCR and the positive CSF was 114 days (from the positivity in October) and was 62 days from the separate onset of symptoms on 23 November.
The study tea commented, “The persistence of a replicable virus in the CNS is only one of the possible explanations for our patient’s presentation, particularly since the typical COVID-19 symptoms (loss of smell and taste) were accompanied by other, less specific symptoms of fatigue, anxiety, headaches, and tingling.”
It must be noted that all the routine preventive measures were taken to avoid possible laboratory cross-contamination of CSF. Moreover, the sample was then aliquoted into three separate analyses (different RNA isolation and PCR runs) to further minimize the possibility of a false-positive result.
The study team warns of CNS viral persistence as a possible mechanism of long-term symptoms at least in some patients.
For more on
SARS-CoV-2 Viral Persistence, keep on logging to Thailand Medical News.
